A vaccine for COVID-19 could become available during the first quarter of 2021. 

The ChAdOx1 nCoV-19 experimental vaccine is being used to test humans globally within all races in order to find a vaccine for a pandemic that has caused a numerous of deaths.

The availability of the vaccine is completely dependent on the clinical trial results. 

“A vaccine could be made commercial as early as the beginning of next year,”

said Professor Shabir Madhi who is Wits University’s principal investigator of the South African VIDA vaccine trial.

Other countries including the United Kingdom and Brazil have been using the same vaccine candidate to test and find a vaccine for Covid-19.  

In South Africa, the trial will be based on 2000 people between the ages of 18 and 65 that are being enrolled for the trial voluntarily. The volunteers will also be monitored 12 months after trial to access the effectiveness of the vaccine. However, Madhi said the results of the volunteers could be seen as early November or December 2020.

Professor Madhi was also part of a panel of experts addressing a World Health Organization media briefing themed COVID-19 and vaccine development in Africa. Covid-19 cases in Africa topped half a million as of Wednesday, with almost 12,000 deaths experienced thus far.

“With regard to the timelines, I think it is possible to have a COVID-19 vaccine that we’re working on as early as the first quarter of next year”. 

Said Madhi

Currently, the focus should remain on trying to slow the rate of transmission of the virus by adhering to the interventions stated by the government

Madhi further stated that the government should put an upfront purchase order for the upcoming vaccine before it is approved in order to reserve supplies of the vaccine.